Identification
- Summary
-
Tigecyclineis a glycylcycline antibiotic used to treat a number of susceptible bacterial infections.
- Brand Names
-
Tygacil
- 基因ric Name
- Tigecycline
- DrugBank Accession Number
- DB00560
- Background
-
Tigecycline is a glycylcycline antibiotic developed and marketed by Wyeth under the brand name Tygacil. It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. Food and Drug Administration (FDA) on June 17, 2005.
- Type
- Small Molecule
- Groups
- Approved
- Structure
-
Structure for Tigecycline (DB00560)
- Weight
-
Average: 585.6487
Monoisotopic: 585.279863249 - Chemical Formula
- C29H39N5O8
- Synonyms
-
- (4S,4aS,5aR,12aS)-9-(2-(tert-butylamino)acetamido)-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
- Tigeciclina
- Tigecycline
- Tigecyclinum
- External IDs
-
- CL-329998
- CL-331002
- DMG-DMDOT
- DMG-MINO
- GAR 936
- GAR-936
- TBG-MINO
- WAY-GAR-936
Pharmacology
- Indication
-
For the treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: Complicated skin and skin structure infections caused byEscherichia coli,Enterococcus faecalis(vancomycin-susceptible isolates only),Staphylococcus aureus(methicillin-susceptible and -resistant isolates),Streptococcus agalactiae,Streptococcus anginosusgrp. (includesS. anginosus,S. intermedius, andS. constellatus),Streptococcus pyogenesandBacteroides fragilis. Complicated intra-abdominal infections caused byCitrobacter freundii,Enterobacter cloacae,Escherichia coli,Klebsiella oxytoca,肺炎克雷伯菌,Enterococcus faecalis(vancomycin-susceptible isolates only),Staphylococcus aureus(methicillin-susceptible isolates only),Streptococcus anginosusgrp. (includesS. anginosus,S. intermedius, andS. constellatus),Bacteroides fragilis,Bacteroides thetaiotaomicron,Bacteroides uniformis,Bacteroides vulgatus,Clostridium perfringens, andPeptostreptococcus micros.
Reduce drug development failure ratesBuild, train, & validate machine-learning models
with evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets. - Associated Conditions
- Contraindications & Blackbox Warnings
-
Avoid life-threatening adverse drug eventsImprove clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support. - Pharmacodynamics
-
Tigecycline is the first clinically-available drug in a new class of antibiotics called the glycylcyclines. Glycylcyclines are a new class of antibiotics derived from tetracycline. These tetracycline analogues are specifically designed to overcome two common mechanisms of tetracycline resistance, namely resistance mediated by acquired efflux pumps and/or ribosomal protection. Glycylcycline antibiotics have a similar mechanism of action as tetracycline antibiotics. Both classes of antibiotics bind to the 30S ribosomal subunit to prevent the amino-acyl tRNA from binding to the A site of the ribosome. However, the glycylcyclines appear to bind more effectively than the tetracyclines.
- Mechanism of action
-
Tigecycline, a glycylcycline, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome. This prevents incorporation of amino acid residues into elongating peptide chains. Tigecycline carries a glycylamido moiety attached to the 9-position of minocycline. The substitution pattern is not present in any naturally occurring or semisynthetic tetracycline and imparts certain microbiologic properties to tigecycline. Tigecycline is not affected by the two major tetracycline resistance mechanisms, ribosomal protection and efflux. Accordingly, tigecycline has demonstrated in vitro and in vivo activity against a broad spectrum of bacterial pathogens. There has been no cross resistance observed between tigecycline and other antibiotics. Tigecycline is not affected by resistance mechanisms such as beta-lactamases (including extended spectrum beta-lactamases), target site modifications, macrolide efflux pumps or enzyme target changes (e.g. gyrase/topoisomerase). In vitro studies have not demonstrated antagonism between tigecycline and other commonly used antibacterial drugs. In general, tigecycline is considered bacteriostatic.
Target Actions Organism A16S ribosomal RNA binderEnteric bacteria and other eubacteria A30S ribosomal protein S9 binder大肠杆菌(应变K12) A30S ribosomal protein S12 binder大肠杆菌(应变K12) A30S ribosomal protein S13 binder大肠杆菌(应变K12) A30S ribosomal protein S14 binder大肠杆菌(应变K12) A30S ribosomal protein S19 binder大肠杆菌(应变K12) - Absorption
-
Not Available
- Volume of distribution
-
Not Available
- Protein binding
-
71% to 89%
- Metabolism
-
Tigecycline is not extensively metabolized. In vitro studies with tigecycline using human liver microsomes, liver slices, and hepatocytes led to the formation of only trace amounts of metabolites. A glucuronide, an N-acetyl metabolite, and a tigecycline epimer (each at no more than 10% of the administered dose) are the primary metabolites.
- Route of elimination
-
Not Available
- Half-life
-
27-43 hours
- Clearance
-
Not Available
- Adverse Effects
-
Improve decision support & research outcomesWith structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data. - Toxicity
-
Since glycylcyclines are similar to tetracyclines, they share many of the same side effects and contraindications as tetracyclines. These side effects may include nausea/vomiting, headache, photosensitivity, discoloration of growing teeth, and fetal damage.
- Pathways
-
Pathway Category Tigecycline Action Pathway Drug action - Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
-
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Tigecycline. Acitretin The risk or severity of pseudotumor cerebri can be increased when Acitretin is combined with Tigecycline. Alitretinoin The risk or severity of pseudotumor cerebri can be increased when Alitretinoin is combined with Tigecycline. Ambroxol The risk or severity of methemoglobinemia can be increased when Tigecycline is combined with Ambroxol. Amoxicillin The therapeutic efficacy of Amoxicillin can be decreased when used in combination with Tigecycline. Ampicillin The therapeutic efficacy of Ampicillin can be decreased when used in combination with Tigecycline. Articaine The risk or severity of methemoglobinemia can be increased when Tigecycline is combined with Articaine. 阿曲库 The therapeutic efficacy of Atracurium can be increased when used in combination with Tigecycline. 阿曲库besylate The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Tigecycline. Azlocillin The therapeutic efficacy of Azlocillin can be decreased when used in combination with Tigecycline. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- No interactions found.
Products
-
Drug product information from 10+ global regionsOur datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions. - Brand Name Prescription Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Tigecycline Injection, powder, lyophilized, for solution 50 mg/5mL Intravenous Fresenius Kabi USA, LLC 2016-12-01 Not applicable US 
Tigecycline Injection, powder, lyophilized, for solution 50 mg/5mL Intravenous Amneal Pharmaceuticals LLC 2018-01-31 Not applicable US Tigecycline Injection, powder, lyophilized, for solution 50 mg/10mL Intravenous Accord Healthcare Inc. 2019-03-28 Not applicable US Tigecycline Powder, for solution 50 mg / vial Intravenous Apotex Corporation 2014-10-23 Not applicable Canada 
Tigecycline Accord Injection, powder, for solution 50 mg Intravenous Accord Healthcare S.L.U. 2020-12-16 Not applicable EU 
Tigecycline Accord Injection, powder, for solution 50 mg Intravenous Accord Healthcare S.L.U. 2020-12-16 Not applicable EU Tigecycline for Injection Powder, for solution 50 mg / vial Intravenous Pharmaris Canada Inc Not applicable Not applicable Canada Tygacil Injection, powder, lyophilized, for solution 50 mg/5mL Intravenous Wyeth Pharmaceuticals Llc, a Subsidiary of Pfizer Inc. 2017-02-08 Not applicable US Tygacil Powder, for solution 50 mg / vial Intravenous Pfizer Canada Ulc 2006-11-30 Not applicable Canada Tygacil Injection, powder, for solution 50 mg Intravenous Pfizer Europe Ma Eeig 2016-09-08 Not applicable EU - 基因ric Prescription Products
-
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Tigecycline Injection, powder, lyophilized, for solution 50 mg/5mL Intravenous Meitheal Pharmaceuticals Inc. 2021-05-13 Not applicable US Tigecycline Injection, powder, lyophilized, for solution 50 mg/1 Intravenous AuroMedics Pharma LLC 2019-06-11 Not applicable US Tigecycline Injection, powder, lyophilized, for solution 50 mg/1 Intravenous Xellia Pharmaceuticals USA LLC 2020-02-01 Not applicable US Tigecycline Injection, powder, lyophilized, for solution 50 mg/5mL Intravenous Apotex Corp 2019-04-09 Not applicable US Tigecycline Injection, powder, lyophilized, for solution 50 mg/10mL Intravenous; Parenteral Sandoz Inc 2017-11-30 Not applicable US
Categories
- ATC Codes
-
J01AA20 — Combinations of tetracyclines
- J01AA — Tetracyclines
- J01A — TETRACYCLINES
- J01 — ANTIBACTERIALS FOR SYSTEMIC USE
- J — ANTIINFECTIVES FOR SYSTEMIC USE
- Drug Categories
- Chemical TaxonomyProvided byClassyfire
-
- Description
- 这种化合物属于类的有机排版ounds known as tetracyclines. These are polyketides having an octahydrotetracene-2-carboxamide skeleton, substituted with many hydroxy and other groups.
- Kingdom
- Organic compounds
- Super Class
- Phenylpropanoids and polyketides
- Class
- Tetracyclines
- Sub Class
- Not Available
- Direct Parent
- Tetracyclines
- Alternative Parents
- Naphthacenes/Anthracenecarboxylic acids and derivatives/Alpha amino acid amides/萘满/Aryl ketones/Dialkylarylamines/的一rylamides/Aralkylamines/Cyclohexenones/Vinylogous acids show 10 more
- Substituents
- Alcohol/Alpha-amino acid amide/Alpha-amino acid or derivatives/Amine/Amino acid or derivatives/Anthracene carboxylic acid or derivatives/Aralkylamine/Aromatic homopolycyclic compound/Aryl ketone/Benzenoid show 30 more
- Molecular Framework
- Aromatic homopolycyclic compounds
- External Descriptors
- tetracyclines (CHEBI:149836)
- Affected organisms
-
- Enteric bacteria and other eubacteria
Chemical Identifiers
- UNII
- 70JE2N95KR
- CAS number
- 220620-09-7
- InChI Key
- FPZLLRFZJZRHSY-HJYUBDRYSA-N
- InChI
-
InChI=1S/C29H39N5O8/c1-28(2,3)31-11-17(35)32-15-10-16(33(4)5)13-8-12-9-14-21(34(6)7)24(38)20(27(30)41)26(40)29(14,42)25(39)18(12)23(37)19(13)22(15)36/h10,12,14,21,31,36,38-39,42H,8-9,11H2,1-7H3,(H2,30,41)(H,32,35)/t12-,14-,21-,29-/m0/s1
- IUPAC Name
-
(4S,4aS,5aR,12aS)-9-[2-(tert-butylamino)acetamido]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide
- SMILES
-
[H][C@@]12CC3=C(C(O)=C(NC(=O)CNC(C)(C)C)C=C3N(C)C)C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
References
- Synthesis Reference
-
Mahdi Fawzi, Tianmin Zhu, Syed Shah, "Tigecycline compositons and methods of preparation." U.S. Patent US20060247181, issued November 02, 2006.
US20060247181 - 基因ral References
- External Links
-
- Human Metabolome Database
- HMDB0014700
- KEGG药物
- D01079
- KEGG Compound
- C12012
- PubChem Compound
- 54686904
- PubChem Substance
- 46509041
- ChemSpider
- 10482314
- BindingDB
- 50247905
- 384455
- ChEBI
- 149836
- ChEMBL
- CHEMBL376140
- ZINC
- ZINC000014879972
- Therapeutic Targets Database
- DAP000880
- PharmGKB
- PA164746412
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Tigecycline
- FDA label
-
Download (170 KB)
Clinical Trials
- Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
-
Phase Status Purpose Conditions Count 4 Completed Not Available Obesity 1 4 Completed Treatment Abdominal Abscess 1 4 Completed Treatment Abscess, Intra-Abdominal/Appendicitis/Diverticulitis/Gallbladder Inflammation/Intraabdominal Infections/Peritonitis 1 4 Completed Treatment Appendicitis/Cross Infection/Diverticulitis/Gallbladder Inflammation/Peritonitis 1 4 Completed Treatment Bacterial skin infections 1 4 Completed Treatment Infection caused by staphylococci 1 4 Completed Treatment Intraabdominal Infections 1 4 Completed Treatment Skin Diseases, Infectious 1 4 Unknown Status Treatment Antibiotic Resistant Infection 1 4 Unknown Status Treatment Bacteremia/Catheter Related Infections 1
Pharmacoeconomics
- Manufacturers
-
- Wyeth pharmaceuticals inc
- Packagers
-
- Chongqing Carelife Pharmaceutical Co. Ltd.
- Patheon Inc.
- Wyeth Pharmaceuticals
- Dosage Forms
-
Form Route Strength Injection, powder, lyophilized, for solution Intravenous 50 mg/1vial Powder 50 mg/1vial Injection Intravenous 50 mg Injection Parenteral Injection, powder, for solution Intravenous 50 mg Powder, for solution Intravenous 50 MG Powder, for solution Powder, for solution Parenteral 50 MG Powder, for solution 50 MG Injection, powder, for solution Parenteral Injection, powder, lyophilized, for solution Intravenous 50 mg/1 Injection, powder, lyophilized, for solution Intravenous 50 mg/5mL Injection, powder, lyophilized, for solution Intravenous 50 mg/10mL Injection, powder, lyophilized, for solution Intravenous; Parenteral 50 mg/10mL Powder, for solution Intravenous 50 mg / vial Injection, powder, lyophilized, for solution Intravenous 50.0 mg Injection, solution Intravenous 50 mg Powder Intravenous 50 mg Injection, solution Intravenous Injection, powder, for solution Intravenous Injection, powder, lyophilized, for solution Intravenous Injection Parenteral 50 mg Injection, powder, lyophilized, for solution Intravenous 50 mg Injection, powder, lyophilized, for solution Intravenous 53 mg Injection Intravenous Injection, powder, for solution 50 mg/1vial - Prices
- Not Available
- Patents
-
Patent Number Pediatric Extension Approved Expires (estimated) Region USRE40086 No 2008-02-19 2013-06-25 US CA2079692 No 2004-06-08 2012-10-02 Canada US8975242 No 2015-03-10 2028-10-24 US US8372995 No 2013-02-12 2030-10-08 US US9254328 No 2016-02-09 2026-03-13 US USRE40183 No 2008-03-25 2016-04-09 US US7879828 No 2011-02-01 2029-02-05 US US9694078 No 2017-07-04 2026-03-13 US US9855355 No 2018-01-02 2033-04-07 US US9855335 No 2018-01-02 2033-04-07 US US10588975 No 2020-03-17 2026-03-13 US
Properties
- State
- Solid
- Experimental Properties
-
Property Value Source logP 0.8 Not Available - Predicted Properties
-
Property Value Source Water Solubility 0.45 mg/mL ALOGPS logP 0.66 ALOGPS logP -3.9 Chemaxon logS -3.1 ALOGPS pKa (Strongest Acidic) 3.17 Chemaxon pKa (Strongest Basic) 8.97 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 11 Chemaxon Hydrogen Donor Count 7 Chemaxon Polar Surface Area 205.76 Å2 Chemaxon Rotatable Bond Count 7 Chemaxon Refractivity 159.34 m3·mol-1 Chemaxon Polarizability 61.56 Å3 Chemaxon Number of Rings 4 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule 是的 Chemaxon - Predicted ADMET Features
-
Property Value Probability Human Intestinal Absorption + 0.8344 Blood Brain Barrier - 0.9836 Caco-2 permeable - 0.5704 P-glycoprotein substrate Substrate 0.9098 P-glycoprotein inhibitor I Non-inhibitor 0.7651 P-glycoprotein inhibitor II Non-inhibitor 0.895 Renal organic cation transporter Non-inhibitor 0.9175 CYP450 2C9 substrate Non-substrate 0.8283 CYP450 2D6 substrate Non-substrate 0.8323 CYP450 3A4 substrate Substrate 0.717 CYP450 1A2 substrate Non-inhibitor 0.8705 CYP450 2C9 inhibitor Non-inhibitor 0.882 CYP450 2D6 inhibitor Non-inhibitor 0.9079 CYP450 2C19 inhibitor Non-inhibitor 0.8592 CYP450 3A4 inhibitor Non-inhibitor 0.9271 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8863 Ames test Non AMES toxic 0.729 致癌性 Non-carcinogens 0.8718 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6895 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9926 hERG inhibition (predictor II) Non-inhibitor 0.6739
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
-
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
insights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
是的
Binder
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
- Kind
- Protein
- Organism
- 大肠杆菌(应变K12)
- Pharmacological action
-
是的
- Actions
-
Binder
- 基因ral Function
- Trna binding
- Specific Function
- The C-terminal tail plays a role in the affinity of the 30S P site for different tRNAs. Mutations that decrease this affinity are suppressed in the 70S ribosome.
- 基因Name
- rpsI
- Uniprot ID
- P0A7X3
- Uniprot Name
- 30S ribosomal protein S9
- 分子量
- 14856.105 Da
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
- Kind
- Protein
- Organism
- 大肠杆菌(应变K12)
- Pharmacological action
-
是的
- Actions
-
Binder
- 基因ral Function
- Trna binding
- Specific Function
- With S4 and S5 plays an important role in translational accuracy.Interacts with and stabilizes bases of the 16S rRNA that are involved in tRNA selection in the A site and with the mRNA backbone. Lo...
- 基因Name
- rpsL
- Uniprot ID
- P0A7S3
- Uniprot Name
- 30S ribosomal protein S12
- 分子量
- 13736.995 Da
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
- Kind
- Protein
- Organism
- 大肠杆菌(应变K12)
- Pharmacological action
-
是的
- Actions
-
Binder
- 基因ral Function
- Trna binding
- Specific Function
- Located at the top of the head of the 30S subunit, it contacts several helices of the 16S rRNA.In the E.coli 70S ribosome in the initiation state (PubMed:12809609) was modeled to contact the 23S rR...
- 基因Name
- rpsM
- Uniprot ID
- P0A7S9
- Uniprot Name
- 30S ribosomal protein S13
- 分子量
- 13099.245 Da
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
- Kind
- Protein
- Organism
- 大肠杆菌(应变K12)
- Pharmacological action
-
是的
- Actions
-
Binder
- 基因ral Function
- Structural constituent of ribosome
- Specific Function
- Binds 16S rRNA, required for the assembly of 30S particles and may also be responsible for determining the conformation of the 16S rRNA at the A site.
- 基因Name
- rpsN
- Uniprot ID
- P0AG59
- Uniprot Name
- 30S ribosomal protein S14
- 分子量
- 11580.36 Da
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
- Kind
- Protein
- Organism
- 大肠杆菌(应变K12)
- Pharmacological action
-
是的
- Actions
-
Binder
- 基因ral Function
- Trna binding
- Specific Function
- In the E.coli 70S ribosome in the initiation state (PubMed:12809609) it has been modeled to contact the 23S rRNA of the 50S subunit forming part of bridge B1a; this bridge is broken in the model wi...
- 基因Name
- rpsS
- Uniprot ID
- P0A7U3
- Uniprot Name
- 30S ribosomal protein S19
- 分子量
- 10430.235 Da
References
- Olson MW, Ruzin A, Feyfant E, Rush TS 3rd, O'Connell J, Bradford PA: Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66. [Article]
- da Silva LM, Nunes Salgado HR: Tigecycline: a review of properties, applications, and analytical methods. Ther Drug Monit. 2010 Jun;32(3):282-8. doi: 10.1097/FTD.0b013e3181dda54f. [Article]
Drug created at June 13, 2005 13:24 / Updated at April 11, 2023 21:33